Erickson Anders W, Das Sunit
Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Division of Neurosurgery, University of Toronto, Toronto, ON, Canada.
Front Oncol. 2019 Aug 23;9:797. doi: 10.3389/fonc.2019.00797. eCollection 2019.
Intracranial metastatic disease (IMD) is a common and severe complication of primary cancers. Current treatment options for IMD include surgical resection and radiation therapy, although there has been recent interest in targeted therapy in the management of IMD. As of yet, insufficient data exist to support the recommendation of targeted therapies in the treatment of IMD. Paradoxically, targeted therapy has been hypothesized to play a role in the development of IMD in patients with primary cancers. This is based on the observations that patients who receive targeted therapy for primary cancer experience prolonged survival, and that prolonged survival has been associated with increased incidence of IMD. Few data exist to clarify if treatment of primary cancers with targeted therapies influences IMD incidence. Here, we discuss the role of targeted therapy in IMD management, review the current literature on IMD incidence and targeted therapy use in primary cancer, and propose the need for future studies to inform physicians in choosing treatment options and counseling patients.
颅内转移性疾病（IMD）是原发性癌症常见且严重的并发症。目前IMD的治疗选择包括手术切除和放射治疗，尽管最近人们对IMD的管理中使用靶向治疗产生了兴趣。截至目前，尚无足够的数据支持在IMD治疗中推荐使用靶向治疗。矛盾的是，有假说认为靶向治疗在原发性癌症患者IMD的发生中起作用。这是基于以下观察结果：接受原发性癌症靶向治疗的患者生存期延长，而生存期延长与IMD发病率增加有关。很少有数据能阐明用靶向治疗原发性癌症是否会影响IMD发病率。在此，我们讨论靶向治疗在IMD管理中的作用，回顾关于IMD发病率和原发性癌症中靶向治疗使用的当前文献，并提出未来研究的必要性，以便为医生选择治疗方案和为患者提供咨询提供依据。
